Most Popular
-
1
Controversial US YouTuber faces travel ban, police investigation
-
2
Thai K-pop fans’ online protest against Hybe intensifies
-
3
Samsung vows to boost AI chip sales after earnings miss
-
4
Pyongyang to bolster readiness against nuclear retaliation: Choe
-
5
SK Innovation becomes Asia-Pacific's largest energy firm after merger
-
6
Korean serial killer 'haunted by victims' ghosts' in prison, TV show reveals
-
7
Yoon's approval rating falls to 19%, all-time low: survey
-
8
No typhoons recorded in S. Korea for the first time in 7 years
-
9
[Robert Fouser] Accepting migrants in South Korea
![[Robert Fouser] Accepting migrants in South Korea](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/10/31/20241031050896_0.jpg&u=)
-
10
Allies say 1953 mutual defense treaty extends to cyber, space threats
![[Robert Fouser] Accepting migrants in South Korea](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/10/31/20241031050896_0.jpg&u=)
Celltrion's COVID-19 antibody treatment wins EU drug agency's recommendation
By YonhapPublished : Nov. 12, 2021 - 10:12
The European Union's drug agency has recommended the approval of a COVID-19 antibody treatment by Celltrion Inc., paving the way for its sales in the region, the South Korean pharmaceutical giant said Friday.
The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency recommended the application of Rekirona in adult patients aged 18 and older.
The European Commission, which is authorized to approve medicines in the region, is expected to issue its decision within two months on the CHMP opinion.
Celltrion is currently conducting a phase three clinical study of Rekirona in 13 countries on 1,315 critically ill COVID-19 patients.
Rekirona is a monoclonal antibody with activity against COVID-19. A monoclonal antibody is a type of protein that has been designed to attach to a specific structure.
It takes the form of an intravenous injection that is directly injected for 60 minutes.
In February, Rekirona won the South Korean drug safety agency's conditional approval, becoming the first locally made treatment for COVID-19.
The drug won its first overseas approval for an emergency application from Indonesia and Brazil.
Celltrion said Rekirona reduces the risk of progressing to severe COVID-19, compared with patients administered with a placebo. The company said the antibody treatment also reduced the recovery time. (Yonhap)
The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency recommended the application of Rekirona in adult patients aged 18 and older.
The European Commission, which is authorized to approve medicines in the region, is expected to issue its decision within two months on the CHMP opinion.
Celltrion is currently conducting a phase three clinical study of Rekirona in 13 countries on 1,315 critically ill COVID-19 patients.
Rekirona is a monoclonal antibody with activity against COVID-19. A monoclonal antibody is a type of protein that has been designed to attach to a specific structure.
It takes the form of an intravenous injection that is directly injected for 60 minutes.
In February, Rekirona won the South Korean drug safety agency's conditional approval, becoming the first locally made treatment for COVID-19.
The drug won its first overseas approval for an emergency application from Indonesia and Brazil.
Celltrion said Rekirona reduces the risk of progressing to severe COVID-19, compared with patients administered with a placebo. The company said the antibody treatment also reduced the recovery time. (Yonhap)
![[Herald Review] ‘Amazon Bullseye,’ motley comedy of forced empathy, outdated wordplay](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=652&simg=/content/image/2024/11/01/20241101050706_0.jpg&u=20241101194716)
